17943
(24R)-24,25-二羟基维生素 D 3
≥98% (vitamin + pre-vitamin, HPLC)
别名:
24,25-二羟胆钙化醇, 司骨化醇
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C27H44O3
化学文摘社编号:
分子量:
416.64
UNSPSC Code:
12352205
NACRES:
NA.79
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
4567039
InChI
1S/C27H44O3/c1-18-8-12-22(28)17-21(18)11-10-20-7-6-16-27(5)23(13-14-24(20)27)19(2)9-15-25(29)26(3,4)30/h10-11,19,22-25,28-30H,1,6-9,12-17H2,2-5H3/b20-10+,21-11-/t19-,22+,23-,24+,25-,27-/m1/s1
SMILES string
[H][C@@]1(CC[C@@]2([H])C(\CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C)[C@H](C)CC[C@@H](O)C(C)(C)O
InChI key
FCKJYANJHNLEEP-XRWYNYHCSA-N
biological source
synthetic
assay
≥98% (vitamin + pre-vitamin, HPLC)
Quality Level
color
white to off-white
storage temp.
−20°C
General description
(24R)-24,25-二羟基维生素 D3（或称司骨化醇）在肾脏中产生。它是活性最高的维生素D形式之一，同时也是必需的循环维生素D3代谢产物。
Application
(24R)-24,25--二羟基维生素D3已被用于评估在原代人间充质干细胞（hMSC）的成骨细胞分化过程中，其与1α,25(OH)2D3的功能比较。
Biochem/physiol Actions
(24R)-24,25-二羟基维生素D3在钙和磷的稳态中起关键作用。(24R)-24,25--二羟基维生素D3与1α25（OH）2D3一起刺激骨代谢。
胆钙化醇是维生素D3的一种失活形式，它在经历各种水平的羟基化后可形成活性的维生素D3类似物。 1α-羟基维生素D3（骨化醇）是一种合成类似物，其可代谢为1,25-二羟胆钙化醇（维生素D3的生物活性形式）。胆钙化醇的其他类似物可由不同的羟基化产生。 24R,25-二羟基维生素D3是25-二羟基维生素D3的分解代谢产物，是发育性骨形成的推定调节剂（putative regulator）。24R,25-二羟基维生素D3是肾25-羟基维生素D3 1α-羟化酶的底物。24R,25-二羟基维生素D3是通过VDR非依赖性信号传导机制调节载脂蛋白A-I （apo A-I ）合成的内源性调节剂，也是通过Ca2 +、PLD和PLC信号传导以及通过LPA-LPA1/3-G(αi)-PI(3)K-mdm2介导的53降解起作用的 Pi诱导的细胞凋亡抑制剂。
Packaging
无底玻璃瓶。内含物装在插入的融合锥内。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
T Yamamoto et al.
Experimental cell research, 244(1), 71-76 (1998-10-15)
The effect of the physiological vitamin D metabolite 24R, 25-dihydroxyvitamin D3 [24R,25(OH)2D3] on human osteoblastic cells was assessed. Physiological concentrations (10(-9)-10(-8) M) of 24R, 25(OH)2D3 significantly increased the cyclic guanosine 5'-monophosphate (cGMP) content in the human osteoblastic cells by approximately
Tove Fall et al.
European journal of heart failure, 14(9), 985-991 (2012-06-23)
Vitamin D deficiency has been associated with risk of overt cardiovascular disease (CVD), but associations with subclinical disease are not well characterized. Hence, we examined associations of circulating vitamin D concentrations and left ventricular (LV) geometry and function by echocardiography
Thomas Edouard et al.
The Journal of clinical endocrinology and metabolism, 97(4), 1243-1249 (2012-02-10)
Several studies suggest that 24,25-dihydroxyvitamin D [24,25(OH)₂D] may have an effect on bone mass and metabolism. We evaluated the relationship between serum 24,25(OH)₂D levels and bone density and bone metabolism in children with a primary bone disorder-osteogenesis imperfecta (OI). The
Kent R Wehmeier et al.
Life sciences, 88(1-2), 110-116 (2010-11-11)
Ligands for the vitamin D receptor (VDR) regulate apolipoprotein A-I (apo A-I) gene expression in a tissue-specific manner. The vitamin D metabolite 24, 25-dihydroxycholecalciferol (24, 25-(OH)(2)D(3)) has been shown to possess unique biological effects. To determine if 24, 25-(OH)(2)D(3) modulates
Helen L Henry
Best practice & research. Clinical endocrinology & metabolism, 25(4), 531-541 (2011-08-30)
Fundamental to understanding the way in which perturbations in the vitamin D endocrine system can affect human health is an appreciation of the steps involved in the production of the well-recognized active hormonal form, 1,25-dihydroxyvitamin D(3). Thus this paper focuses
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持